Furthermore, reduced IGFBP-3 expression may be a risk factor for advanced clinicopathologic classification and poor patient survival and could serve as a prognostic marker for the evaluation of ESCC patients18. This evidence concerns the gene IGFBP3 and esophageal squamous cell carcinoma.